In the last few decades, the PI3K/Akt signaling pathway has been assumed as being dysregulated in a wide range of human malignancies, with kinase mutations and/or decreased PTEN expression leading to tumor transformation.Cancer cells’ increasing reliance on PI3K/Akt signaling makes it an attractive therapeutic target. The gene discussed is AKT1; the disease is cancer.